Testing eye-surface inflammation in glaucoma or high eye pressure
Part of Eyes & vision clinical trials.
This study measures inflammation markers on the eye surface in people with primary open-angle glaucoma or ocular hypertension who use certain glaucoma drops. The results may help doctors understand how these drops affect the eye and inflammation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are over 18 years old.
- You have primary open-angle glaucoma or ocular hypertension (high eye pressure).
- You have been using one of these drops for at least 3 months: tafluprost 0.0015% or latanoprost 0.005% (with BAK 0.2 mg/ml) or latanoprost 0.005%.
- If you have ocular hypertension and no glaucoma treatment yet, you must be treatment-naïve for that condition.
- No eye conditions or eye-surface problems other than glaucoma/high eye pressure (and none that are active within the last 6 months).
- No eye surgery in the last 6 months, and no contact lens use in the last 4 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether three different eye drop treatments (netarsudil, latanoprost, or both together) can improve blood flow to the white part of the eye and the retina. It may help people with high eye pressure or who are glaucoma suspects better understand how these treatments work.
This trial tests a new eye drop combination (TFC-003) to lower eye pressure in people with primary open-angle glaucoma or ocular hypertension. It compares the new drug to existing treatments to see if it works better or is safer.
This Phase 3 study compares two versions of the same glaucoma eye-drop medicine (bimatoprost 0.01%) to see how similarly they work and their effect on eye pressure. It may help people with chronic open-angle glaucoma or ocular hypertension who need treatment in both eyes.
This study looks at how glaucoma and its treatments affect the surface of the eye and proteins in tears. It may help find better ways to manage eye health in people with glaucoma.
This study tests a new eye drop medicine (DNN.31.19.026) to lower pressure inside the eye for people with glaucoma or ocular hypertension. The goal is to see if it works safely when combined with other eye pressure medications.
This study compares a special contact lens that measures eye pressure with standard eye-pressure testing. It may help people with glaucoma or ocular hypertension by improving how pressure is monitored.
Hear when a new Glaucoma, Open-Angle trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.